About this document
Belite Bio by blueberry94 is a document available to read on EtoBox.
Belite Bio, Inc. is preparing for an initial public offering of American Depositary Shares (ADS) to raise $36 million, targeting the treatment of macular degeneration with its lead asset LBS-008, a novel oral Retinol Binding Protein 4 antagonist. The company has significant backing from its principal shareholder, Lin Bioscience International Ltd., and aims to address an unmet market need as there are currently no approved treatments for Stargardt disease and dry age-related macular degeneration. The managem
- Author
- blueberry94
- Language
- EN